UMR2-705 is a novel Tumor Necrosis Factor Receptor 2 (TNFR2) agonist peptide, promotes Tregs expansion without affecting CD8+ T cells or conventional effector T cells (Teffs), acting through TNFR2 signaling.
UMR2-705 induces dose-dependent expansion of Tregs in murine CD4+ T cells and human PBMCs. selectively promotes Treg expansion through TNFR2 signaling.
UMR2-705 (25 mg/kg/day x 3 days) increases the proportion of Tregs in the spleen and lymph nodes in Balb/c mice.
UMR2-705 mitigates LPS-induced systemic inflammation and cytokine production, promotes dendritic cell accumulation in vivo and enhances their capacity to expand regulatory T cells in vitro.
UMR2-705 activates inflammation-associated signaling pathways, increases expression of multiple members of the TNF receptor superfamily, including Tnfrsf10b (TRAILR2), Tnfrsf9 (4-1BB), Tnfrsf18 (GITR), Tnfrsf1b (TNFR2), and Tnfrsf4 (OX40), on CD4+ T cells.